Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
Neoplasms, Breast
About this trial
This is an interventional treatment trial for Neoplasms, Breast focused on measuring breast cancer
Eligibility Criteria
Inclusion criteria: Tumor accessible for multiple biopsies ECOG (Eastern Cooperative Oncology Group) performance status 0-2 Adequate bone marrow Renal and hepatic function LVEF (left ventricular ejection fraction) greater than 0% based on ECHO (echocardiogram) or MUGA (multigated acquisition). Exclusion criteria: Females who are pregnant or nursing. Any unstable, pre-existing major medical condition. Received an investigational drug within the past 4 weeks. Had major surgery in the past 2 weeks. Currently receiving amiodarone or has received amiodarone in the past 6 months.
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
Arms of the Study
Arm 1
Experimental
Overall study
A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.